Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

NCT07563881 is registered in ClinicalTrials.gov with Rapport Therapeutics Inc. as lead sponsor.

NCT NCT07563881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07563881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Lead sponsor
Rapport Therapeutics Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
June 5, 2026
Completion date
September 30, 2029
Enrollment
333 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, focal epilepsy, focal seizure